University of Minnesota 
Welcome,         Profile    Billing    Logout  
 4 Products   0 Diseases  4 Products   8 Trials   158 News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
FT516 / Fate Therap
NCT04551885: FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
12
US
FT516, Avelumab, Bavencio, Cyclophosphamide, Fludarabine, IL-2, Proleukin, Aldesleukin
Fate Therapeutics
Solid Tumor, Adult
08/23
08/23
FT516-101, NCT04023071: FT516 in Subjects With Advanced Hematologic Malignancies

Terminated
1
72
US
FT516, Rituximab, Rituxan, MabThera, Obinutuzumab, Gazyva, Cyclophosphamide, Fludarabine, IL-2, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Acute Myelogenous Leukemia, B-cell Lymphoma
10/23
10/23
FT500 / Fate Therap, University of Minnesota
NCT04106167: Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Terminated
N/A
20
US
Allogeneic natural killer (NK) cell
Fate Therapeutics
Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
08/23
08/23
FT538 / Fate Therap
NCT04614636: FT538 in Subjects With Advanced Hematologic Malignancies

Terminated
1
42
US
FT538, Cyclophosphamide, Fludarabine, Daratumumab, Darzalex, Elotuzumab, Empliciti
Fate Therapeutics
Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma
07/23
08/23
NCT05069935: FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
16
US
FT538, NK Cell Therapy, Cyclophosphamide, Cy, Fludarabine, Flu, Monoclonal antibody - Dose Escalation, mAb, Monoclonal antibody - Dose Expansion
Fate Therapeutics
Solid Tumor, Adult
08/23
08/23
NCT05700630: Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

Withdrawn
1
34
US
FT538, Vorinostat
Masonic Cancer Center, University of Minnesota
HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency, Lymphoid Tissue; Infection, Interleukin
07/24
08/24
NCT04714372: FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

Completed
1
9
US
Daratumumab/rHuPH20, Darzalex, FT538, Fludarabine, FLUDARA, Cyclophosphamide, CYTOXAN, NEOSAR
Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia, Myeloid Leukemia, Monocytic Leukemia
01/24
10/24
NCT05708924: MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Terminated
1
1
US
FT538, Enoblituzumab, RES242, MGA271
Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI)
Cancer, Solid Tumor, Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
08/24
08/24
Undisclosed CISH inactivated TIL / Intima Biosci, University of Minnesota
2019LS002, NCT04426669: A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Active, not recruiting
1/2
20
US
Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL), Aldesleukin, Interleukin-2, IL-2
Intima Bioscience, Inc., Masonic Cancer Center, University of Minnesota
Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal, Gastrointestinal Cancer, Colo-rectal Cancer, Pancreatic Cancer, Gall Bladder Cancer, Colon Cancer, Esophageal Cancer, Stomach Cancer
01/26
01/26
NCT04089891: A Study in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

Not yet recruiting
1/2
41
NA
Lymphodepleting Chemotherapy Regimen, Tumor-Infiltrating Lymphocytes (TIL), Aldesleukin
Masonic Cancer Center, University of Minnesota
Gastrointestinal Epithelial Cancer
10/24
10/24
CheckCell-2, NCT05566223: CISH Inactivated TILs in the Treatment of NSCLC

Not yet recruiting
1/2
70
US
Fludarabine, Fludara, Cyclophosphamide, Cytoxan, CISH Inactivated TIL, Aldesleukin, Proleukin, Interleukin-2, IL-2, Pembrolizumab, Keytruda
Intima Bioscience, Inc.
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
11/25
11/27
GBM6-AD / University of Minnesota
NCT02549833: Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma

Completed
1
28
US
GBM6-AD and poly-ICLC before and after surgery, GBM6-AD and poly-ICLC after surgery only
Jennie Taylor, University of Minnesota
Oligodendroglioma, Astrocytoma, Grade II, Glioma, Astrocytic, Glioma, Malignant Glioma, Oligoastrocytoma, Mixed
08/22
08/24
NCT06305910: CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

Recruiting
1
24
US
Treatment with CD200AR-L, Imiquimod, GBM6-AD, Single dose of radiation (300 cGy)
OX2 Therapeutics
Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
09/25
01/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
FT516 / Fate Therap
NCT04551885: FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
12
US
FT516, Avelumab, Bavencio, Cyclophosphamide, Fludarabine, IL-2, Proleukin, Aldesleukin
Fate Therapeutics
Solid Tumor, Adult
08/23
08/23
FT516-101, NCT04023071: FT516 in Subjects With Advanced Hematologic Malignancies

Terminated
1
72
US
FT516, Rituximab, Rituxan, MabThera, Obinutuzumab, Gazyva, Cyclophosphamide, Fludarabine, IL-2, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Acute Myelogenous Leukemia, B-cell Lymphoma
10/23
10/23
FT500 / Fate Therap, University of Minnesota
NCT04106167: Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Terminated
N/A
20
US
Allogeneic natural killer (NK) cell
Fate Therapeutics
Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
08/23
08/23
FT538 / Fate Therap
NCT04614636: FT538 in Subjects With Advanced Hematologic Malignancies

Terminated
1
42
US
FT538, Cyclophosphamide, Fludarabine, Daratumumab, Darzalex, Elotuzumab, Empliciti
Fate Therapeutics
Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma
07/23
08/23
NCT05069935: FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
16
US
FT538, NK Cell Therapy, Cyclophosphamide, Cy, Fludarabine, Flu, Monoclonal antibody - Dose Escalation, mAb, Monoclonal antibody - Dose Expansion
Fate Therapeutics
Solid Tumor, Adult
08/23
08/23
NCT05700630: Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

Withdrawn
1
34
US
FT538, Vorinostat
Masonic Cancer Center, University of Minnesota
HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency, Lymphoid Tissue; Infection, Interleukin
07/24
08/24
NCT04714372: FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

Completed
1
9
US
Daratumumab/rHuPH20, Darzalex, FT538, Fludarabine, FLUDARA, Cyclophosphamide, CYTOXAN, NEOSAR
Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia, Myeloid Leukemia, Monocytic Leukemia
01/24
10/24
NCT05708924: MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Terminated
1
1
US
FT538, Enoblituzumab, RES242, MGA271
Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI)
Cancer, Solid Tumor, Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
08/24
08/24
Undisclosed CISH inactivated TIL / Intima Biosci, University of Minnesota
2019LS002, NCT04426669: A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Active, not recruiting
1/2
20
US
Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL), Aldesleukin, Interleukin-2, IL-2
Intima Bioscience, Inc., Masonic Cancer Center, University of Minnesota
Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal, Gastrointestinal Cancer, Colo-rectal Cancer, Pancreatic Cancer, Gall Bladder Cancer, Colon Cancer, Esophageal Cancer, Stomach Cancer
01/26
01/26
NCT04089891: A Study in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

Not yet recruiting
1/2
41
NA
Lymphodepleting Chemotherapy Regimen, Tumor-Infiltrating Lymphocytes (TIL), Aldesleukin
Masonic Cancer Center, University of Minnesota
Gastrointestinal Epithelial Cancer
10/24
10/24
CheckCell-2, NCT05566223: CISH Inactivated TILs in the Treatment of NSCLC

Not yet recruiting
1/2
70
US
Fludarabine, Fludara, Cyclophosphamide, Cytoxan, CISH Inactivated TIL, Aldesleukin, Proleukin, Interleukin-2, IL-2, Pembrolizumab, Keytruda
Intima Bioscience, Inc.
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
11/25
11/27
GBM6-AD / University of Minnesota
NCT02549833: Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma

Completed
1
28
US
GBM6-AD and poly-ICLC before and after surgery, GBM6-AD and poly-ICLC after surgery only
Jennie Taylor, University of Minnesota
Oligodendroglioma, Astrocytoma, Grade II, Glioma, Astrocytic, Glioma, Malignant Glioma, Oligoastrocytoma, Mixed
08/22
08/24
NCT06305910: CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

Recruiting
1
24
US
Treatment with CD200AR-L, Imiquimod, GBM6-AD, Single dose of radiation (300 cGy)
OX2 Therapeutics
Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
09/25
01/27

Download Options